{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:45:01Z","timestamp":1791402301509,"version":"4.3.3"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal de Mycologie M\u00e9dicale"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.mycmed.2017.11.003","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T08:32:16Z","timestamp":1523867536000},"page":"379-383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study"],"prefix":"10.1016","volume":"28","author":[{"given":"L.","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.-F.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.-W.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-Y.","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.-P.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-N.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mycmed.2017.11.003_bib0005","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2017.11.003_bib0010","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1086\/587177","article-title":"Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death","volume":"46","author":"Cornely","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2017.11.003_bib0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","article-title":"Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy","volume":"47","author":"Trotti","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.mycmed.2017.11.003_bib0020","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"D\u00f6ring","year":"2007","journal-title":"New Eng J Med"},{"key":"10.1016\/j.mycmed.2017.11.003_bib0025","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"New Eng J Med"},{"key":"10.1016\/j.mycmed.2017.11.003_bib0030","doi-asserted-by":"crossref","first-page":"738","DOI":"10.5414\/CP201880","article-title":"Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study","volume":"51","author":"Shen","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.mycmed.2017.11.003_bib0035","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2174\/157488711796575595","article-title":"Posaconazole: a new antifungal weapon","volume":"6","author":"Aperis","year":"2011","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.mycmed.2017.11.003_bib0040","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/ICO.0b013e3181870315","article-title":"The use of voriconazole in the treatment of cylindrocarpon keratomycosis","volume":"28","author":"Mitra","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.mycmed.2017.11.003_bib0045","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenia patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2017.11.003_bib0050","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fun#infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter Prospective Antifungal Therapy (PATH) Alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2017.11.003_bib0055","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1086\/504328","article-title":"Safety of long-term oral term oral posaconazole use in the treatment of refractory invasive fungal invasive fungal infections","volume":"42","author":"Raad","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2017.11.003_bib0060","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1517\/13543784.11.3.409","article-title":"Review of the safety and efficacy of voriconazole","volume":"11","author":"Hoffman","year":"2002","journal-title":"Expert Opin Investing Drugs"},{"key":"10.1016\/j.mycmed.2017.11.003_bib0065","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00277-010-0939-8","article-title":"Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands","volume":"89","author":"Jansen","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.mycmed.2017.11.003_bib0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2146\/ajhp110149","article-title":"Cost effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in US patients with graft-versus-host disease","volume":"69","author":"O'Sullivan","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.mycmed.2017.11.003_bib0075","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3111\/13696998.2010.542393","article-title":"Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system","volume":"14","author":"Michallet","year":"2011","journal-title":"J Med Econ"},{"key":"10.1016\/j.mycmed.2017.11.003_bib0080","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.bbmt.2016.12.505","article-title":"Comparison of posaconazole versus voriconazole in the induction of acute myeloid leukemia: impact on cost, safety, and efficacy","volume":"23","author":"Antosz","year":"2017","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Journal de Mycologie M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1156523317303323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1156523317303323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:19:07Z","timestamp":1761110347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1156523317303323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1156523317303323"],"URL":"https:\/\/doi.org\/10.1016\/j.mycmed.2017.11.003","relation":{},"ISSN":["1156-5233"],"issn-type":[{"value":"1156-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Journal de Mycologie M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mycmed.2017.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}